Experts emphasize the need to continue to focus on healthy dietary and lifestyle practices
MONDAY, Jan. 12, 2026 (HealthDay News) — Cessation of weight management medications (WMMs) is followed by rapid weight regain and reversal of beneficial effects on cardiometabolic markers, according to a review published online Jan. 7 in The BMJ.
Sam West, Ph.D., from the University of Oxford in the United Kingdom, and colleagues conducted a systematic literature review to quantify and compare the rate of weight regain after cessation of WMMs in adults with overweight or obesity.
Based on 37 included studies (9,341 participants), the average monthly rate of weight regain was 0.4 kg (mixed model, 0.3 kg monthly versus control in randomized controlled trials) during an average treatment duration of 39 weeks and an average follow-up of 32 weeks. Within 1.4 years after the cessation of WMMs, all cardiometabolic markers were projected to return to baseline. Compared with cessation of behavioral weight management programs, weight regain was faster after cessation of WMMs (by 0.3 kg monthly), independent of initial weight loss.
“GLP-1 receptor agonists should not be relied on as a magic cure for treating obesity,” Qi Sun, M.D., from Brigham and Women’s Hospital in Boston, writes in an accompanying editorial. “Healthy dietary and lifestyle practices should remain the foundation for obesity treatment and management, with medications such as GLP-1 receptor agonists used as adjuncts.”
Three authors disclosed ties to the Novo Nordisk Foundation.
Study IDs Risk Factors for Ketoacidosis in Adults With T2D Receiving SGLT2 Inhibitors
Anifrolumab Tied to Lower Hospitalization, Infection Risk in Lupus
Recommendations Updated for Management of Anemia in CKD
Therapies Compared for Newly Diagnosed Multiple Sclerosis
Initial Rx Length Tied to Long-Term Use of Z-Drugs
Azacitidine + Venetoclax Tied to Improved Event-Free Survival in Adults With AML
Maintaining Physical Activity Tied to Better Quality of Life With Multiple Sclerosis
Updated Recommendations Address Medications to Prevent Migraine in Adults